U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C24H22F3N5O5.ClH
Molecular Weight 553.918
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of AGERAFENIB HYDROCHLORIDE

SMILES

Cl.COC1=CC2=C(C=C1OC)C(OC3=CC(NC(=O)NC4=NOC(=C4)C(C)(C)C(F)(F)F)=CC=C3)=NC=N2

InChI

InChIKey=XCZIYUDQUDWQHI-UHFFFAOYSA-N
InChI=1S/C24H22F3N5O5.ClH/c1-23(2,24(25,26)27)19-11-20(32-37-19)31-22(33)30-13-6-5-7-14(8-13)36-21-15-9-17(34-3)18(35-4)10-16(15)28-12-29-21;/h5-12H,1-4H3,(H2,30,31,32,33);1H

HIDE SMILES / InChI

Molecular Formula C24H22F3N5O5
Molecular Weight 517.4572
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/24930831 | https://www.ncbi.nlm.nih.gov/pubmed/22319199

CEP-32496 (RXDX 105) is an orally administered, small molecule, VEGFRsparing, RET, BRAF, EGFR tyrosine kinase inhibitor, for the treatment of solid tumours, including malignant melanoma and colorectal cancer. CEP-32496 was originally discovered by Ambit Biosciences (now Daiichi Sankyo) and Cephalon (now owned by Teva) as part of a research programme to develop orally administered kinase inhibitors. The worldwide rights to the compound were licensed to Teva by Ambit, following the acquisition of Cephalon by Teva. Teva, in March 2015, entered into an asset purchase agreement with Ignyta, pursuant to which, Ignyta has acquired worldwide rights and assets of four oncology development programmes, including CEP-32496. Following the acquisition of the compound by Ignyta, CEP 32496 has been renamed to RXDX 105. Phase I/Ib development of RXDX 105 for the treatment of advanced solid tumours is underway in the US.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Identification of 1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea hydrochloride (CEP-32496), a highly potent and orally efficacious inhibitor of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF) V600E.
2012 Feb 9
Patents

Sample Use Guides

CEP-32496 was evaluated for antitumor efficacy and tolerability in several BRAFV600E-driven human carcinoma xenograft mouse models, including both Colo-205 and A375. Athymic nu/nu nude mice (6-8 week old, 20−25 g) were dosed orally for 14 days with either vehicle only (22% 2-hydroxypropyl-beta-cyclodextrin) or with CEP-32496 at 10, 30, or 100 mg/kg twice daily (BID), and each dose of drug was given in a volume of 0.1 mL per 20 g of body weight. All doses were well tolerated, with no mortality or significant body weight loss (<5% relative to vehicle matched controls) observed during treatment or up to 1 week post dosing. Dosing at 10 mg/kg BID had little effect on tumor growth compared to the control group. However, increasing the dose to either 30 or 100 mg/kg BID resulted in significant efficacy.
Route of Administration: Oral
CEP-32496 has demonstrated potent and sustained antiproliferative activity in nanomolar range against A375, Colo-679, Colo-205, SK-MEL-28, HT-144, cell lines expressing BRAFV600E. The CEP-32496 were added at various concentrations with a final DMSO concentration of 0.5% and incubated for 72 h.
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:13:47 GMT 2023
Edited
by admin
on Fri Dec 15 16:13:47 GMT 2023
Record UNII
8J0Y5N290S
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
AGERAFENIB HYDROCHLORIDE
Common Name English
CEP-32496 HYDROCHLORIDE
Common Name English
Code System Code Type Description
FDA UNII
8J0Y5N290S
Created by admin on Fri Dec 15 16:13:47 GMT 2023 , Edited by admin on Fri Dec 15 16:13:47 GMT 2023
PRIMARY
CAS
1227678-26-3
Created by admin on Fri Dec 15 16:13:47 GMT 2023 , Edited by admin on Fri Dec 15 16:13:47 GMT 2023
PRIMARY
PUBCHEM
56954675
Created by admin on Fri Dec 15 16:13:47 GMT 2023 , Edited by admin on Fri Dec 15 16:13:47 GMT 2023
PRIMARY
SMS_ID
100000175134
Created by admin on Fri Dec 15 16:13:47 GMT 2023 , Edited by admin on Fri Dec 15 16:13:47 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY